James Leon Khatcheressian
About
James Khatcheressian, M.D., is a hematologist and oncologist practicing in Richmond, Virginia, with specialty training in internal medicine. His clinical work focuses on the treatment and management of cancer, with particular attention to breast cancer, metastatic disease, and supportive oncology care.
His research contributions span approximately 20 peer-reviewed publications, appearing in journals such as JAMA, the Journal of Clinical Oncology, and The Oncologist. He has contributed to American Society of Clinical Oncology clinical practice guidelines on topics including endocrine therapy for hormone receptor-positive metastatic breast cancer, breast cancer follow-up and management after primary treatment, adjuvant ovarian ablation in early-stage breast cancer, and the use of white blood cell growth factors. His published work also includes clinical trials examining zoledronic acid dosing intervals for patients with bone metastases, pazopanib as second-line therapy in advanced renal cell carcinoma, and a pilot study of decision aids for communicating prognostic information to patients with advanced cancer receiving chemotherapy. He practices at Virginia Cancer Institute in Richmond.
Credentials
Publications
- Randomized Phase II Study of Ramucirumab or Icrucumab in Combination with Capecitabine in Patients with Previously Treated Locally Advanced or Metastatic Breast Cancer.
- Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.
- Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline.
- Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update.
- Pazopanib as second-line treatment after sunitinib or bevacizumab in patients with advanced renal cell carcinoma: a Sarah Cannon Oncology Research Consortium Phase II Trial.
- Breast cancer follow-up and management after primary treatment: American Society of Clinical Oncology clinical practice guideline update.
- American Society of Clinical Oncology endorsement of the cancer care Ontario practice guideline on adjuvant ovarian ablation in the treatment of premenopausal women with early-stage invasive breast cancer.
- A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer.
- Giving honest information to patients with advanced cancer maintains hope.
- Ovarian suppression in the management of premenopausal breast cancer: methods and efficacy in adjuvant and metastatic settings.
Request CV and rates
Tell us about your case and we'll connect you with James Leon Khatcheressian within two business days.
Other Internal Medicine experts
Verified specialists available for your case.
